- Home
- ACV vs CATX Comparison
ACV vs CATX Comparison
Compare ACV & CATX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACV
- CATX
- Stock Information
- Founded
- ACV 2015
- CATX 1983
- Country
- ACV United States
- CATX United States
- Employees
- ACV N/A
- CATX N/A
- Industry
- ACV Finance/Investors Services
- CATX Medical/Dental Instruments
- Sector
- ACV Finance
- CATX Health Care
- Exchange
- ACV Nasdaq
- CATX Nasdaq
- Market Cap
- ACV 197.6M
- CATX 182.9M
- IPO Year
- ACV N/A
- CATX N/A
- Fundamental
- Price
- ACV $21.16
- CATX $2.34
- Analyst Decision
- ACV
- CATX Strong Buy
- Analyst Count
- ACV 0
- CATX 10
- Target Price
- ACV N/A
- CATX $13.89
- AVG Volume (30 Days)
- ACV 38.8K
- CATX 619.9K
- Earning Date
- ACV 01-01-0001
- CATX 05-12-2025
- Dividend Yield
- ACV 9.20%
- CATX N/A
- EPS Growth
- ACV N/A
- CATX N/A
- EPS
- ACV N/A
- CATX N/A
- Revenue
- ACV N/A
- CATX $1,454,000.00
- Revenue This Year
- ACV N/A
- CATX N/A
- Revenue Next Year
- ACV N/A
- CATX N/A
- P/E Ratio
- ACV N/A
- CATX N/A
- Revenue Growth
- ACV N/A
- CATX 1.40
- 52 Week Low
- ACV $16.82
- CATX $1.60
- 52 Week High
- ACV $23.74
- CATX $19.10
- Technical
- Relative Strength Index (RSI)
- ACV 65.77
- CATX 51.17
- Support Level
- ACV $20.25
- CATX $2.18
- Resistance Level
- ACV $20.58
- CATX $2.65
- Average True Range (ATR)
- ACV 0.38
- CATX 0.16
- MACD
- ACV 0.19
- CATX 0.02
- Stochastic Oscillator
- ACV 89.79
- CATX 56.25
About ACV Virtus Diversified Income & Convertible Fund of Beneficial Interest
Virtus AllianzGI Diversified Income & Convertible Fund is a diversified, limited-term, closed-end management investment company. The fund's investment objective is to provide total return through a combination of current income and capital appreciation while seeking to provide downside protection against capital loss. It invests in a diversified portfolio of convertible securities, income-producing equity securities, and income-producing debt and other instruments of varying maturities, of which a majority of the managed assets are invested in convertibles.
About CATX Perspective Therapeutics Inc.
Perspective Therapeutics Inc is a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body. The Company has a proprietary technology that utilizes the alpha-emitting isotope Lead-212 (212Pb) to deliver powerful radiation specifically to cancer cells via specialized targeting moieties.